Loading clinical trials...
Loading clinical trials...
Multiple myeloma (MM) survival has been improved during the last decade owing to new treatments. Hence, it has become a matter of importance to precisely define the depth of MM response to therapy. 18...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University Hospital, Bordeaux
NCT05091372 · Myeloma Multiple
NCT04268199 · Myeloma, Myeloma Multiple
NCT07236021 · Metastatic Cancers, Myeloma Multiple
NCT05932680 · Myeloma Multiple
NCT06911710 · Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia), and more
Bordeaux University Hospital - Haut-Lévêque
Pessac
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions